C16 Biosciences vs Karius
Side-by-side comparison of AI visibility scores, market position, and capabilities
C16 Biosciences produces Palmless, a biofermentation-derived alternative to palm oil targeting the beauty, personal care, and food industries; raised $20M Series A led by Breakthrough Energy Ventures;
About
C16 Biosciences is a biotechnology company founded in 2017 by David Heller, Irina Gerry, and Harry McNamara and headquartered in New York City. The company developed a proprietary biomanufacturing platform that uses engineered yeast fermentation to produce Palmless — a sustainable, palm oil-equivalent ingredient designed for beauty, personal care, and food applications. Palm oil is one of the most widely used commodity oils in the world, but its production is responsible for massive tropical deforestation, habitat destruction, and biodiversity loss, particularly in Indonesia and Malaysia. C16's fermentation approach produces oils with the same functional performance as palm oil — high saturation, solid at room temperature, neutral flavor — without any agricultural land conversion.
Karius raised $409M total including a $100M Series C in May 2024; its genomic blood test detects 1,000+ pathogens at 400+ U.S. hospitals; launched Karius Focus BAL for pneumonia in April 2025.
About
Karius is a Redwood City, CA-based life sciences company founded in 2014 that developed the Karius Test — a single blood draw that uses next-generation sequencing and AI to detect over 1,000 pathogens (bacteria, fungi, viruses, parasites) in seriously ill patients. The test is used when conventional cultures and targeted diagnostics fail, providing clinicians at transplant centers, children''s hospitals, and ICUs with a comprehensive pathogen report within 24 hours.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.